These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 38570412)

  • 1. The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications.
    Menozzi E; Schapira AHV
    CNS Drugs; 2024 May; 38(5):315-331. PubMed ID: 38570412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats.
    van Kessel SP; Bullock A; van Dijk G; El Aidy S
    mSystems; 2022 Feb; 7(1):e0119121. PubMed ID: 35076270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiota-mediated effects of Parkinson's disease medications on Parkinsonian non-motor symptoms in male transgenic mice.
    Radisavljevic N; Metcalfe-Roach A; Cirstea M; Tabusi MM; Bozorgmehr T; Bar-Yoseph H; Finlay BB
    mSphere; 2024 Jan; 9(1):e0037923. PubMed ID: 38078745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Helicobacter pylori on Levodopa Pharmacokinetics.
    Nyholm D; Hellström PM
    J Parkinsons Dis; 2021; 11(1):61-69. PubMed ID: 33164946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease.
    Leta V; Klingelhoefer L; Longardner K; Campagnolo M; Levent HÇ; Aureli F; Metta V; Bhidayasiri R; Chung-Faye G; Falup-Pecurariu C; Stocchi F; Jenner P; Warnecke T; Ray Chaudhuri K;
    Eur J Neurol; 2023 May; 30(5):1465-1480. PubMed ID: 36757008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.
    Cui C; Han Y; Li H; Yu H; Zhang B; Li G
    Front Cell Infect Microbiol; 2022; 12():887407. PubMed ID: 36034698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gut microbiome in Parkinson's disease: A culprit or a bystander?
    Keshavarzian A; Engen P; Bonvegna S; Cilia R
    Prog Brain Res; 2020; 252():357-450. PubMed ID: 32247371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain-gut-microbiota axis in Parkinson's disease.
    Mulak A; Bonaz B
    World J Gastroenterol; 2015 Oct; 21(37):10609-20. PubMed ID: 26457021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stomaching the Possibility of a Pathogenic Role for Helicobacter pylori in Parkinson's Disease.
    McGee DJ; Lu XH; Disbrow EA
    J Parkinsons Dis; 2018; 8(3):367-374. PubMed ID: 29966206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Interplay between Gut Microbiota and Parkinson's Disease: Implications on Diagnosis and Treatment.
    Varesi A; Campagnoli LIM; Fahmideh F; Pierella E; Romeo M; Ricevuti G; Nicoletta M; Chirumbolo S; Pascale A
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helicobacter pylori eradication for Parkinson's disease.
    Rees K; Stowe R; Patel S; Ives N; Breen K; Clarke CE; Ben-Shlomo Y
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008453. PubMed ID: 22071847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperine improves levodopa availability in the 6-OHDA-lesioned rat model of Parkinson's disease by suppressing gut bacterial tyrosine decarboxylase.
    Hu X; Yu L; Li Y; Li X; Zhao Y; Xiong L; Ai J; Chen Q; Wang X; Chen X; Ba Y; Wang Y; Wu X
    CNS Neurosci Ther; 2024 Feb; 30(2):e14383. PubMed ID: 37528534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiota- Brain-Gut-Axis Relevance to Parkinson's Disease: Potential Therapeutic Effects of Probiotics.
    Raj K; Singh S; Chib S; Mallan S
    Curr Pharm Des; 2022; 28(37):3049-3067. PubMed ID: 36200207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probiotics modulate gastrointestinal microbiota after
    He C; Xie Y; Zhu Y; Zhuang K; Huo L; Yu Y; Guo Q; Shu X; Xiong Z; Zhang Z; Lyu B; Lu N
    Front Immunol; 2022; 13():1033063. PubMed ID: 36426355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease.
    Hashim H; Azmin S; Razlan H; Yahya NW; Tan HJ; Manaf MR; Ibrahim NM
    PLoS One; 2014; 9(11):e112330. PubMed ID: 25411976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease mechanisms as subtypes: Microbiome.
    Bonvegna S; Cilia R
    Handb Clin Neurol; 2023; 193():107-131. PubMed ID: 36803806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal microbiome and
    Sitkin S; Lazebnik L; Avalueva E; Kononova S; Vakhitov T
    World J Gastroenterol; 2022 Feb; 28(7):766-774. PubMed ID: 35317277
    [No Abstract]   [Full Text] [Related]  

  • 18. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease.
    van Kessel SP; Frye AK; El-Gendy AO; Castejon M; Keshavarzian A; van Dijk G; El Aidy S
    Nat Commun; 2019 Jan; 10(1):310. PubMed ID: 30659181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Helicobacter pylori infection and Parkinson's Disease: etiology, pathogenesis and levodopa bioavailability.
    Wei BR; Zhao YJ; Cheng YF; Huang C; Zhang F
    Immun Ageing; 2024 Jan; 21(1):1. PubMed ID: 38166953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Avenues for Parkinson's Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota.
    Lorente-Picón M; Laguna A
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33804226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.